Document:

EX-10.v

 Exhibit 10v 
 *Confidential Treatment Requested 
  

 
 AMENDED AND RESTATED 

CLOPIDOGREL 

INTELLECTUAL PROPERTY LICENSE AGREEMENT 
 between 
 SANOFI 

and 
 SANOFI PHARMA
BRISTOL-MYERS SQUIBB 
 dated as of January 1, 2013 

 
  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
	ARTICLE 1	  			
	DEFINITIONS	  			
	 1.1.
	 	Defined Terms	  	 	2	  
	 1.2.
	 	Additional Defined Terms	  	 	5	  
		
	ARTICLE 2	  			
	GRANT OF LICENSE	  			
	 2.1.
	 	License Grant	  	 	6	  
	 2.2.
	 	No Transfer	  	 	6	  
	 2.3.
	 	No Implicit Rights	  	 	6	  
	 2.4.
	 	Goodwill	  	 	6	  
	 2.5.
	 	Location-Gérance	  	 	6	  
		
	ARTICLE 3	  			
	SUB-LICENSE	  			
	 3.1.
	 	General Sub-License	  	 	6	  
	 3.2.
	 	Termination of Sub-License	  	 	7	  
		
	ARTICLE 4	  			
	CONSIDERATION	  			
	 4.1.
	 	Discoverer’s Remuneration	  	 	7	  
	 4.2.
	 	Adjustment to the Discovery Royalty	  	 	7	  
	 4.3.
	 	Payment	  	 	8	  
	 4.4.
	 	Method of Payment	  	 	8	  
	 4.5.
	 	Records	  	 	8	  
	 4.6.
	 	Taxes	  	 	8	  
		
	ARTICLE 5	  			
	TRADEMARKS; PATENTS; INFRINGEMENT	  			
	 5.1.
	 	Maintenance	  	 	9	  
	 5.2.
	 	Registration	  	 	9	  
	 5.3.
	 	Undertaking of the SNC Partnership	  	 	9	  
	 5.4.
	 	Compliance	  	 	9	  
	 5.5.
	 	Quality Standards	  	 	9	  
	 5.6.
	 	Quality Control	  	 	10	  
	 5.7.
	 	Failure to Meet Standards	  	 	10	  
	 5.8.
	 	Patent and Trademark Infringement	  	 	10	  
	 5.9.
	 	Notification of Infringement	  	 	10	  
	 5.10.
	 	Invalidity or Nullity	  	 	11	  
	 5.11.
	 	Original License	  	 	11	  
	 5.12.
	 	[*]	  	 	11	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 i 

							
	ARTICLE 6	  			
	TERM; TERMINATION	  			
	 6.1.
	 	Term; Termination	  	 	12	  
	 6.2.
	 	Consequences of Termination	  	 	13	  
		
	ARTICLE 7	  			
	CONFIDENTIALITY	  			
		
	ARTICLE 8	  			
	MISCELLANEOUS	  			
	 8.1.
	 	Notices	  	 	13	  
	 8.2.
	 	Governing Law	  	 	15	  
	 8.3.
	 	Dispute Resolution	  	 	15	  
	 8.4.
	 	Specific Performance	  	 	16	  
	 8.5.
	 	No Third Party Beneficiaries	  	 	16	  
	 8.6.
	 	Assignment	  	 	16	  
	 8.7.
	 	Severability	  	 	16	  
	 8.8.
	 	Waivers and Amendments	  	 	17	  
	 8.9.
	 	Headings	  	 	17	  
	 8.10.
	 	Entire Agreement	  	 	17	  
	 8.11.
	 	No Partnership or Joint Venture	  	 	17	  
	 8.12.
	 	BMS Partner	  	 	17	  
	 8.13.
	 	Governing Language	  	 	17	  
	 8.14.
	 	Force Majeure	  	 	18	  
	 8.15.
	 	Counterparts	  	 	18	  
	 8.16.
	 	Definitive Agreement	  	 	18	  
		
	SCHEDULES	  			
		
	 SCHEDULE 1A LICENSED PATENTS
	  			
	 SCHEDULE 1B LICENSED TRADEMARKS
	  			
	 SCHEDULE 1C TERRITORY A
	  			

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 ii 

 This AMENDED AND RESTATED CLOPIDOGREL INTELLECTUAL PROPERTY LICENSE AGREEMENT (this
“Agreement”) dated as of January 1, 2013, is hereby made by and between: 
 Sanofi, a
société anonyme organized and existing under the laws of the French Republic (“Licensor”); and 
 Sanofi Pharma Bristol-Myers Squibb, a société en nom collectif organized and existing under the laws of the French Republic (the “SNC Partnership” and, together with
Licensor, the “Parties” and, individually, each a “Party”). 
 WITNESSETH: 

WHEREAS, Licensor previously discovered and patented a new chemical entity known as SR 25990C with the international non-proprietary name
Clopidogrel Hydrogenosulphate (“Clopidogrel”); 
 WHEREAS, Licensor and Bristol-Myers Squibb Company, a
Delaware corporation (“BMS”) have entered into a Territory A Alliance Support Agreement dated as of January 1, 1997 (the “Alliance Support Agreement”) and have formed through their indirect wholly owned
subsidiaries the SNC Partnership for, among other things, the commercialization of Clopidogrel Products in Territory A (as such terms are defined in the Alliance Support Agreement); 

WHEREAS, Licensor and the SNC Partnership have entered into a Clopidogrel Intellectual Property License and Supply Agreement, dated as of
January 1, 1997, as amended by the Amendment to the Clopidogrel Intellectual Property License and Supply Agreement, dated May 25, 2010 (as amended, the “Original License”) pursuant to which Licensor granted to the SNC
Partnership a license under certain intellectual property, including certain patents, trademarks and know-how, for the commercialization of Clopidogrel Products in Territory A; 

WHEREAS, the SNC Partnership has been commercializing Clopidogrel Products in Territory A since that date; 

WHEREAS, pursuant to the Master Restructuring Agreement (the “Definitive Agreement”), dated as of September 27,
2012, by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to Clopidogrel Products; and 

WHEREAS, in connection with the transactions contemplated by the Definitive Agreement, Sanofi and BMS have agreed to (among other things)
(i) terminate the Alliance Support Agreement and (ii) amend and restate the Original License on the terms set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and the terms and conditions set forth herein, the Parties hereby agree to amend and restate the Original License as follows: 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 ARTICLE 1 
 DEFINITIONS 
 1.1. Defined Terms. As used in this Agreement, the
following terms shall have the following meanings: 
 “Affiliate”, when used with reference to
any Person, means any other Person controlling, controlled by, or under common control with, such Person; provided, however, that, with respect to Licensor, the definition of Affiliate shall exclude L’Oréal, a societe
anonyme organized and existing under the laws of the French Republic. For the purposes of this definition, “control” shall refer to (a) the possession, directly or indirectly, of the power to direct the management or
policies of a Person or to veto any material decision relating to the management or policies of a Person, in each case whether through the ownership of voting securities, by contract or otherwise, (b) the beneficial ownership, directly or
indirectly, of securities (excluding general partnership interests) representing at least 50% of the voting power of all outstanding voting securities of a Person or (c) the beneficial ownership of at least 50% of the partnership interests of a
general partnership. 
 “BMS Partner” means BMS Investco S.A.S., a partner in the SNC
Partnership. 
 “Clopidogrel Bulk” means the active substance chemical bulk containing
Clopidogrel. 
 “Clopidogrel Intellectual Property” means the Clopidogrel Know-How and the
Licensed Patents. 
 “Clopidogrel Know-How” means any and all technical data, information,
material and other know-how that relate to the manufacturing and purification of the Clopidogrel Bulk, including, without limitation, any analytical methodology, chemical, procedures, protocols, techniques and results of experimentation and testing,
solely owned, developed or acquired by Licensor and its Affiliates as of the date hereof. 

“Clopidogrel Product” means (i) a product with the sole active ingredient
Clopidogrel, in finished form, marketed under the trademarks Plavix® and Iscover® or any trademark that is confusingly similar to or that is a replacement for any such trademark, and (ii) a
product (an “Identified Clopi FDC”) which contains as the only active ingredients the combination of Clopidogrel with acetylsalicylic acid, in finished form, marketed under the trademarks DuoPlavin®, CoPlavix® and DuoCover® or any
trademark that is confusingly similar to or that is a replacement for any such trademark. For the avoidance of doubt, Clopidogrel Products shall exclude any Fixed Dose Combination Products. 

“Competing Product” means any product [*] that [*], but which is not [*] that is [*] or that is a [*]
selected for such [*] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2 

 “Cost of Bulk” means the [*] 

“Effective Date” means January 1, 2013. 

“fixed dose combination” means a pharmaceutical dosage form containing fixed doses of more than one
active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in which separate drugs in separate dosage forms are sold in a single unit or
bundle. 
 “Fixed Dose Combination Product” means a fixed dose combination containing
Clopidogrel (other than the Identified Clopi FDCs). 
 “Governmental Authority” means any
federal, state or local or any foreign or supranational government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal or judicial or arbitral body. 

“Identified Clopi FDC” has the meaning set forth in the definition of Clopidogrel Product. 

“IFRS Net Sales” means, with respect to a Clopidogrel Product, net sales of Licensor (or its Affiliates
or their respective licensees or sublicensees) as audited and reported in Euros by Licensor (or its Affiliates or licensees) in accordance with International Financial Reporting Standards (“IFRS”), as IFRS may be modified from time
to time. For the avoidance of doubt: (a) IFRS Net Sales shall not include samples, compassionate use of the Clopidogrel Products and the like; provided that revenue from Clopidogrel Products sold to third parties for clinical trial
purposes shall be included in IFRS Net Sales; and (b) any Damages (as defined in the Definitive Agreement) paid by Licensor pursuant to Article IX of the Definitive Agreement shall not be treated as a deduction for purposes of calculating IFRS
Net Sales. In calculating IFRS Net Sales, the Parties shall disregard any related Know-How, Discovery or other royalties paid to Licensor after January 1, 2013 on Clopidogrel Products. 

“Lease Agreement” means the Business Lease Agreement between the SNC Partnership and Sanofi Winthrop
Industrie, dated as of the date hereof. 
 “Licensed Intellectual Property” means the
Clopidogrel Intellectual Property and the Product Intellectual Property. 
 “Licensed Patents”
means the patents and patent applications of Licensor and its Affiliates existing on the date hereof that relate to Clopidogrel Products in Territory A as listed on Schedule 1A attached hereto and all reissues, renewals, divisions,
continuations, continuations-in-part, reexaminations, patent term restorations, patents of additions and extensions thereof. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3 

 “Licensed Trademarks” means the trademarks and registered
trademarks and applications for registered trademarks in Territory A listed on Schedule 1B attached hereto, and any trademarks, registered trademarks and applications for registered trademarks that are confusingly similar to or replacements
for any of the foregoing and that are selected by Licensor for use in connection with Clopidogrel Products. 

“Loss of Exclusivity” means the loss of exclusivity in any country in Territory A upon the occurrence of
all of the three following conditions: (i) a Clopidogrel Product shall have lost its marketing exclusivity (whether by virtue of compulsory license under, or expiration, invalidity or unenforceability of, the patents covering such Clopidogrel
Product, loss or expiration of any exclusivity conferred de facto or de jure by any statutory marketing or data exclusivity or any other cause), (ii) one or more Competing Products shall have been legally marketed in such country
by one or more Third Parties and (iii) IFRS Net Sales of such Clopidogrel Product in such country over any period of [*] (after the conditions set forth in sub-clauses (i) and (ii) above shall have been satisfied) shall have [*] the
level of IFRS Net Sales of such Clopidogrel Product in such country over the immediately preceding period of [*] 

“MAA” means any marketing authorizations, licenses, approvals, registrations, certificates and exemptions
submitted to or granted by or pending with any Governmental Authority for the purpose of allowing the manufacture, production, supply, marketing, distribution or sale of any Clopidogrel Product in a particular country. 

“Market Penetration” means, with respect to one or more Competing Products marketed by one or more Third
Parties in any given country in Territory A, the number of units of such Competing Products sold in such country, expressed as a percentage of the sum of (i) [*] with respect to which [*] constitute [*] and (ii) the [*] in each case over a
period of [*], as reported by [*]. 
 “Marketing Entity” means, in each country in Territory A,
one or more entities selected by the SNC Partnership (or the entity to which the SNC Partnership leases its business pursuant to the Lease Agreement) to be responsible for the marketing, promotion, sale and distribution of the Clopidogrel Products.

 “New IP Agreement” means the FDC Intellectual Property License Agreement between Sanofi and
BMS, dated as of the date hereof. 
 “Person” means any individual, partnership, firm,
corporation, société anonyme, société en nom collectif, société en participation, société par actions simplifiée, limited liability company, joint venture, association,
trust or other entity or any government or any agency or political subdivision thereof, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended.

 “Product Intellectual Property” means the Product Know-How, the Licensed Trademarks and the
Licensed Patents. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4 

 “Product Know-How” means any and all technical data,
information, material and other know-how that relate to the formulation of Clopidogrel Products, including, without limitation, any analytical methodology, chemical, toxicological, pharmacological and clinical data, formulae, procedures, protocols,
techniques and results of experimentation and testing, solely owned, developed or acquired by Licensor as of the date hereof. 
 “Sanofi Partner” means Sanofi Participations, a partner in the SNC Partnership. 
 “Territory A” means the countries and geographic areas described and listed in Schedule 1C attached hereto. 

“Third Party” means a Person who or which is neither a Party nor an Affiliate of a Party. 

“U.S.” or “United States” means any State or Commonwealth of the United States of
America, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa and any other territory, possession or military base of the United States of America. 

1.2. Additional Defined Terms. The following additional defined terms shall have the meanings set forth in the sections of this
Agreement listed below: 
  

			
	 Defined Term
	  	Section Where Defined
	 Agreement
	  	Preamble
	 Alliance Support Agreement
	  	Recitals
	 BMS
	  	Recitals
	 Clopidogrel
	  	Recitals
	 Definitive Agreement
	  	Recitals
	 Discovery Royalty
	  	4.1
	 Dispute

Dispute Resolution Notice
	  	8.3
 8.3

	 Force Majeure

ICC
	  	8.14
 8.3

	 IFRS
	  	1.1
	 License Termination Date
	  	6.2(a)
	 Licensor
	  	Preamble
	 Notices
	  	8.1
	 Original License
	  	Recitals
	 Party
	  	Preamble
	 Quality Standards
	  	5.5
	 SNC Partnership
	  	Preamble

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5 

 ARTICLE 2 
 GRANT OF LICENSE 
 2.1. License Grant. Subject to the terms and
conditions of this Agreement, Licensor hereby grants to the SNC Partnership, and the SNC Partnership hereby accepts: 
 (i) an exclusive license for the term hereof under the Product Intellectual Property to make, have made, sell, offer for sale and import Clopidogrel Products in Territory A; and 

(ii) an exclusive license for the term hereof under the Clopidogrel Intellectual Property solely for the purpose of making
and having Clopidogrel made to produce Clopidogrel Products for Territory A by the entity(ies) approved by Licensor; 
 provided, that,
the foregoing exclusivity shall not apply to Licensor and BMS to the extent of their respective rights under the New IP Agreement with respect to Fixed Dose Combination Products, and Licensor retains all rights under the Product Intellectual
Property and Clopidogrel Intellectual Property with respect to Fixed Dose Combination Products, subject to the licenses granted to BMS under the New IP Agreement. 
 2.2. No Transfer. The SNC Partnership hereby acknowledges and agrees that this Agreement does not, and shall not be deemed to, transfer any proprietary ownership interest whatsoever to the SNC
Partnership in or to the Licensed Intellectual Property. Nothing herein shall give the SNC Partnership any right, title or interest in or to any of the Licensed Intellectual Property, except the rights granted pursuant to this Agreement. 

2.3. No Implicit Rights. All of the rights granted hereunder are explicitly stated herein and nothing in this Agreement shall be
construed to grant any implied rights whatsoever to the SNC Partnership in or to the Licensed Intellectual Property. 
 2.4.
Goodwill. The SNC Partnership hereby acknowledges that all goodwill connected with the Licensed Trademarks shall inure to the benefit of Licensor, and the SNC Partnership shall not take any action that may be detrimental to such goodwill.

 2.5. Location-Gérance. For the avoidance of doubt, Sections 2.2 – 2.4 hereof shall not prevent the SNC
Partnership from leasing its business pursuant to the Lease Agreement. 
 ARTICLE 3 

SUB-LICENSE 
 3.1. General Sub-License. The SNC Partnership shall not, without the prior written consent of Licensor, sub-license any of its rights and obligations under this Agreement, except as permitted
under, and subject to the terms of, the Lease Agreement. No such sub-license shall relieve the SNC Partnership of its obligations hereunder. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6 

 3.2. Termination of Sub-License. Licensor shall have the right to require the SNC
Partnership to terminate any sub-license hereunder in the event that the sub-licensee fails to comply in any material respect with, or takes any action contrary to, the terms of such sub-license, and such sub-licensee has failed to remedy such
non-compliance within thirty (30) days from its receipt of written notice thereof from Licensor or the SNC Partnership. 

ARTICLE 4 

CONSIDERATION 
 4.1. Discoverer’s Remuneration. In consideration of the rights and licenses granted hereunder, the SNC Partnership shall pay, or shall cause to be paid, directly to Licensor for the term
hereof an aggregate amount equal to [*] of IFRS Net Sales of Clopidogrel Products in Territory A (the “Discovery Royalty”), which shall be subject to adjustment in accordance with Section 4.2 hereof. 

4.2. Adjustment to the Discovery Royalty. (a) The Discovery Royalty shall be reset, and shall subsequently be subject to
periodic positive or negative adjustments (but not more than once every two (2) consecutive calendar quarters), as described below: 
 The rate of the Discovery Royalty shall be [*] of IFRS Net Sales of Clopidogrel Products in Territory A, [*] an amount equal to [*] which shall be determined as follows: 

[*] 
 (the Cost of Bulk being computed over [*] immediately preceding the calculation date and expressed as a percentage of IFRS Net Sales); provided, however, that, except as provided in
paragraphs (b) and (d) of this Section 4.2, the Discovery Royalty shall in no event be reduced below [*] of IFRS Net Sales of Clopidogrel Products in Territory A. 

(b) From and after the Loss of Exclusivity of a Clopidogrel Product in any given country in Territory A, Licensor shall receive a
trademark royalty of [*] of IFRS Net Sales of such Clopidogrel Product in such country, if and for so long as the Licensed Trademarks are used by a Marketing Entity in such country, and any [*] in the rate of the Discovery Royalty attributable to
such country remaining after [*] (if applicable) shall be [*] gradually, on the basis of [*]: 
 [*] 

(c) The Loss of Exclusivity shall be measured by Licensor on a quarterly basis with the adjustment occurring at the beginning of the
quarter following the quarter in which the Loss of Exclusivity occurs. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7 

 (d) Notwithstanding the provisions of Section 4.1 and paragraphs (a), (b) and
(c) of this Section 4.2, the Parties hereby agree that the Discovery Royalty payable by the SNC Partnership to Licensor for the years 2013 until 2018 (inclusive) shall be equal to an amount of [*] of IFRS Net Sales of Clopidogrel Products
in Territory A and shall not be subject to the royalty rates set forth in Section 4.1 or the adjustments set forth in paragraphs (a), (b) and (c) above. 
 4.3. Payment. For the term of this Agreement, the SNC Partnership shall pay or cause to be paid to Licensor all amounts due hereunder on a quarterly basis within sixty (60) days of the end of
each calendar quarter. Each such payment shall be accompanied by an accurate statement of the amount of IFRS Net Sales of Clopidogrel Products in Territory A during such calendar quarter, the calculation of all payments to be made to Licensor for
such calendar quarter and, except for the years 2013 – 2018 inclusive, a report on Competing Products and on any actual or potential Market Penetration. 
 4.4. Method of Payment. (a) All payments to be made hereunder shall be made by wire transfer in immediately available funds, and shall be made in Euros to the bank account of Licensor as
notified to the SNC Partnership, unless the Parties agree to settle such payments through other means. 
 (b) Amounts due from
the SNC Partnership to Licensor in respect of sales based on a currency other than Euros shall be converted to Euros using the methodology determined for such purpose by Licensor in calculating IFRS Net Sales. 

4.5. Records. The SNC Partnership shall maintain (i) books, records and accounts which accurately and fairly reflect, in
reasonable detail, the IFRS Net Sales of Clopidogrel Products in Territory A and (ii) an adequate system of internal accounting controls. All books, records and accounts referred to in clause (i) above shall be maintained for not less than
[*] or for such longer period if and as required by applicable law, following the date of the sales constituting the IFRS Net Sales and shall be made available for reasonable review upon request by Licensor. 

4.6. Taxes. All payments due under this Agreement shall be paid in full without deduction, except for taxes (if any) required to
be withheld by applicable law in Territory A with respect to such payments. In the event the SNC Partnership is required under applicable law to withhold any tax to the revenue authorities in any country in Territory A regarding any payment to
Licensor, the amount of such tax shall be deducted by the SNC Partnership and paid to the relevant revenue authority, and the SNC Partnership shall notify Licensor thereof and shall promptly furnish to Licensor all copies of any tax certificate or
other documentation evidencing such withholding. In the event that any such tax shall subsequently be found to be due, payment of such tax shall be the responsibility of Licensor. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8 

 ARTICLE 5 
 TRADEMARKS; PATENTS; INFRINGEMENT 
 5.1. Maintenance. Licensor shall
maintain in full force and effect all Licensed Patents and Licensed Trademarks for the term of this Agreement and shall bear all costs and expenses related thereto. In the event that Licensor or the SNC Partnership becomes aware of a registration
for or an application to register a tradename, trademark, service mark, certification mark or logo which it believes is reasonably likely to conflict with any Licensed Trademark, it shall promptly inform the other Party in writing of the same,
giving particulars thereof. Licensor shall have the first right to commence an opposition or cancellation proceeding against such application or registration. If Licensor decides not to commence an opposition or cancellation proceeding, it shall
promptly inform the SNC Partnership in writing of the same and the SNC Partnership shall have the right, but not the obligation, to commence an opposition or cancellation proceeding against the application or registration. The cost and expenses of
any such opposition or cancellation proceeding commenced by either Licensor or the SNC Partnership shall be borne in accordance with Section 7.2 of the Definitive Agreement. Each Party shall execute all necessary and proper documents and take
such actions as shall be appropriate to assist the other Party in commencing and prosecuting such opposition or cancellation proceeding. 
 5.2. Registration. The Licensed Trademarks in Territory A are filed and shall be maintained in the name of Licensor. The SNC Partnership shall execute and deliver to Licensor, in such form as
Licensor shall reasonably request, any and all documents which may be necessary or desirable to assist Licensor in renewing the Licensed Trademarks, or in recording the SNC Partnership as a registered user of the Licensed Trademarks, if necessary.

 5.3. Undertaking of the SNC Partnership. The SNC Partnership agrees not to register or attempt to register in any
country in Territory A any trade name, trademark, service mark, certification mark or logo that is confusingly similar to, or that contains elements that are confusingly similar to, any Licensed Trademark. 

5.4. Compliance. The SNC Partnership shall comply with all notice and marking requirements under applicable intellectual property
laws and labeling requirements under applicable law that are necessary or advisable for the protection and enforcement of the Licensed Trademarks or the Licensed Patents. The SNC Partnership shall further comply with all applicable laws and
regulations related to the manufacture, marketing, distribution and sale of Clopidogrel Products in Territory A. 
 5.5.
Quality Standards. The SNC Partnership shall make or have made Clopidogrel Products according to the quality standards established in accordance with the MAAs (the “Quality Standards”). All promotional and packaging materials
to be used in connection with Clopidogrel Products shall be submitted to Licensor so that Licensor may ensure the correct use of the Licensed Trademarks thereon, and the SNC Partnership shall not use any such promotional or packaging materials
without the prior consent of Licensor (which consent shall not be unreasonably withheld); provided, however, that such consent shall be deemed to have been given if Licensor shall not have provided Notice to the SNC Partnership of its
objection to any such promotional or packaging material within fifteen (15) days after its receipt thereof. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9 

 5.6. Quality Control. If the SNC Partnership uses manufacturers other than Licensor
or its Affiliates, the SNC Partnership shall carry out quality control tests that are customary in the pharmaceutical industry to determine that all Clopidogrel Products and packaging related thereto sold by or on behalf of the SNC Partnership
conform to the Quality Standards. The SNC Partnership shall keep full and complete testing records, which shall be made available for reasonable review upon request by Licensor. Upon reasonable request, the SNC Partnership shall permit Licensor to
inspect the manufacturing facilities used by or on behalf of the SNC Partnership and, during such inspection, Licensor shall have the right to make such tests as it deems necessary to ensure that the Quality Standards are being maintained.

 5.7. Failure to Meet Standards. The SNC Partnership agrees that Clopidogrel Products not meeting the Quality Standards
shall not be labeled or used or offered for sale under the Licensed Trademarks. Unless otherwise agreed, any products that are not Clopidogrel Products, including, without limitation, Competing Products, may not be advertised or otherwise promoted,
directly or indirectly, by the SNC Partnership with any reference to the Licensed Trademarks, and the SNC Partnership shall instruct its distributors to comply with this restriction. 

5.8. Patent and Trademark Infringement. During the term of this Agreement, if the SNC Partnership or Licensor becomes aware of the
infringement or threatened infringement of any Licensed Patent or Licensed Trademark, it shall promptly notify the other Party in writing of the same, giving particulars thereof. Licensor shall have the first right to institute an action based on
such infringement or threatened infringement and shall be responsible for the conduct of such action. The SNC Partnership shall assist and cooperate with Licensor to the extent necessary in the conduct of such action. If Licensor notifies the SNC
Partnership in writing that it does not propose to take action against the infringer, or if within two (2) months of notification of the infringement or threatened infringement, Licensor has taken no demonstrable action to enjoin or address
such infringement or threatened infringement against the infringer, the SNC Partnership shall have the right, but not the obligation, to institute an infringement action. The costs and expenses of any such infringement action (including, without
limitation, fees of attorneys and other professionals) shall be borne in accordance with [*]. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to institute and
prosecute such infringement actions and Licensor shall, if required, lend its name to enable the SNC Partnership to conduct the proceedings. Any award or other consideration paid by Third Parties as a result of an infringement action (whether by way
of settlement or otherwise) shall be allocated between Licensor and BMS in accordance with [*]. 
 5.9. Notification of
Infringement. In the event of the institution of any suit by a Third Party against either Party or any of their respective Affiliates for patent and/or trademark infringement and/or infringement of any other intellectual property rights
involving Clopidogrel 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 10 

 
or Clopidogrel Products in Territory A, such Party shall promptly notify the other Party in writing of such suit. Licensor shall have the first right to conduct the defense of any such suit.
Licensor shall notify the SNC Partnership within a reasonable amount of time after notification of the institution of such a suit if it elects not to defend such suit. If Licensor does not elect to defend such suit, the SNC Partnership shall have
the right, but not the obligation, to conduct the defense of such suit. The costs and expenses of any such suit (including, without limitation, fees of attorneys and other professionals) shall be borne in accordance with Article IX of the Definitive
Agreement. Each Party hereby agrees to assist and cooperate with the other Party, to the extent necessary, in the defense of such suit. Any award or other consideration paid by a Third Party as a result of such suit (whether by way of settlement or
otherwise) shall be allocated between Licensor and BMS as follows: (a) [*] and (b) [*]. 
 5.10. Invalidity or
Nullity. Licensor shall have the first right to conduct the defense of any suit brought by a Third Party based on the invalidity or nullity of a Licensed Patent other than an action instituted by way of counterclaim in an action for infringement
of a Licensed Patent, in which case the Party conducting the infringement action shall have the right to conduct the defense. The SNC Partnership shall assist and cooperate with Licensor to the extent necessary in the defense of such suit. If
Licensor notifies the SNC Partnership in writing that it does not propose to conduct the defense of such suit, or if within two (2) months of notification of such suit, Licensor has taken no demonstrable action to conduct the defense of such
suit, the SNC Partnership shall have the right, but not the obligation, to conduct the defense of such suit. The costs and expenses of any such action (including, without limitation, fees of attorneys and other professionals) shall be borne in
accordance with Article IX of the Definitive Agreement. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to conduct the defense of such suit and Licensor shall, if
required, lend its name to enable the SNC Partnership to conduct the proceedings. Any award or other consideration paid by a Third Party as a result of such suit (whether by way of settlement or otherwise) shall be allocated between Licensor and BMS
as follows: (a) [*] and (b) [*]. 
 5.11. Original License. The Parties hereby agree that all acts, omissions
and occurrences prior to the Effective Date relating to the subject matter of this Article 5, and all rights and obligations of the Parties with respect thereto, shall be governed by the terms of the Original License prior to its amendment and
restatement in accordance with the terms hereof, subject to Section 7.2(b) of the Definitive Agreement. 
 5.12. [*]
Notwithstanding anything to the contrary contained herein, Licensor shall have no obligation to maintain, prosecute or defend any patent set forth on Schedule 1A hereto under the heading [*]. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 11 

 ARTICLE 6 
 TERM; TERMINATION 
 6.1. Term; Termination. 

(a) The term of this Agreement shall commence on the date hereof and shall expire on the later of (x) the 15th anniversary of the
first commercial sale of a Clopidogrel Product and (y) such date as the last Licensed Patent effective in any country in Territory A shall have expired and all other de jure exclusivity available for a Clopidogrel Product shall have
ended. Thereafter, the term of this Agreement may be renewed for successive three-year terms, respectively, by the mutual agreement of the Parties no later than 24 months prior to the expiration of the term then in effect. 

(b) This Agreement may be terminated by the mutual written consent of Licensor, the SNC Partnership and BMS. 

(c) Licensor shall have the right to declare termination of this Agreement upon Notice to the SNC Partnership, following the first to
occur of: 
 (i) the BMS Partner shall have (A) voluntarily commenced any proceeding or filed any petition
seeking relief under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the French
Republic or any other applicable jurisdiction, (B) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its
property, (C) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (D) made a general assignment for the benefit of creditors of all or substantially all of its assets,
(E) become unable generally, or admitted in writing its inability to, pay all or substantially all of its debts as they become due or (F) taken corporate action for the purpose of effecting any of the foregoing; or 

(ii) an involuntary proceeding shall have been commenced or any involuntary petition shall have been filed in a court of
competent jurisdiction seeking (A) relief in respect of the BMS Partner, or of its property, under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy,
insolvency or similar law of the United States, any state thereof, the French Republic or any other applicable jurisdiction, (B) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for
the BMS Partner or for all or substantially all of its property or (C) the winding-up or liquidation of the BMS Partner; and such proceeding or petition shall have continued undismissed for sixty (60) days or an order or decree approving
or ordering any of the foregoing shall have continued unstayed and in effect for thirty (30) days. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 12 

 6.2. Consequences of Termination. (a) Upon the expiration or early termination
of this Agreement pursuant to Section 6.1 hereof (the “License Termination Date”): 
 (i)
the SNC Partnership shall cease, and shall cause each sub-licensee (if any) to cease, all activities related to the Licensed Intellectual Property; and 
 (ii) the SNC Partnership shall pay in full all amounts due to Licensor hereunder within ten (10) days after the final determination of IFRS Net Sales for such period, including the License
Termination Date, pursuant to Sections 4.3, 4.4 and 4.6 hereof which shall survive until the full payment of all amounts under this clause (ii). 
 (b) Expiration or early termination of this Agreement pursuant to this Article 6 shall be without prejudice to any rights which shall have accrued to the benefit of any Party prior to such expiration or
termination. Such expiration or termination shall not relieve any Party from its obligations which are expressly indicated to survive the expiration or termination of this Agreement. All of the Parties’ rights and obligations under this
subclause (b) and under Sections 4.5, 4.6, 6.2, 8.2 – 8.4, Article 7 and, with respect to actions or suits commenced prior to the date of expiration or early termination hereof and until each such action or suit is finally resolved,
Sections 5.1, 5.8, 5.9 and 5.10 hereof, shall survive such expiration or termination for the applicable period. 
 ARTICLE 7

 CONFIDENTIALITY 
 All of the data, material and information exchanged by the Parties hereunder or related hereto (including, without limitation, the Licensed Intellectual Property) shall be subject to the confidentiality
provisions of the Definitive Agreement as set forth in Section 8.8 thereof. 
 ARTICLE 8 

MISCELLANEOUS 
 8.1. Notices. All notices, requests or other communications hereunder (collectively, “Notices”) shall be in writing, shall be in the English language and shall be given or made by
delivery in person, by courier service, by facsimile (with receipt confirmed) or by registered or certified mail (return receipt requested, with postage prepaid) to the respective Parties at the following addresses: 

If to Licensor, to: 
 Sanofi 
 54, rue la Boétie 

75008 Paris, France 
 Attention: Senior Vice President, Legal Affairs and General Counsel 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 13 

 Facsimile: (33.1) 53.77.43.03 

Attention: Vice President, Alliances & Partnerships 
 Facsimile: (33.1) 53.77.40.99 
 with a copy to: 

Weil Gotshal & Manges 
 767 Fifth Avenue 
 New York NY 10153 

Attention: [omitted] 
 Facsimile: 212 310 8007 
 If to the SNC Partnership, to: 

Sanofi Pharma Bristol-Myers Squibb 
 54, rue la Boétie 
 75008 Paris, France 

Attention: Senior Vice President, Legal Affairs and General Counsel 

Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 
 Facsimile: (33.1)
53.77.40.99 
 with a copy to the BMS Partner at: 
 Bristol-Myers Squibb Company 
 P.O. Box 4000 

Route 206 & Province Line Road 
 Princeton, NJ 08543-4000 USA 
 Attention: Vice President and Associate General
Counsel, Transactional Practice Group 
 Facsimile: (1-609) 252-7680 

and: 
 Wilmer
Cutler Pickering Hale and Dorr LLP 
 7 World Trade Center 

250 Greenwich Street 
 New York, NY 10007 USA 
 Attention: [omitted] 

Facsimile: (212) 230-8888 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 14 

 or to such other address or facsimile number as hereafter shall be furnished as provided in this
Section 8.1 by any Party hereto to the other Party hereto. All Notices given to any Party in accordance with this Section 8.1 shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or
sent by facsimile, or on the date ten (10) business days after dispatch by certified or registered mail (postage prepaid) if mailed. 
 8.2. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States of America, without regard to the choice of law principles
that might otherwise be applied in such jurisdiction. 
 8.3. Dispute Resolution. 

(a) Negotiation and Notice. In the event of any dispute, claim, controversy or disagreement (each, a “Dispute”)
arising out of, in connection with or relating to this Agreement including any question regarding this Agreement’s existence, validity or termination, the Parties shall first seek resolution of such Dispute by negotiation between their
respective senior management. Such negotiation shall be deemed to commence upon the service by either Licensor or the BMS Partner upon the other of a written notice (a “Dispute Resolution Notice”) under this
Section 8.3(a). 
 (b) If a Dispute subject to negotiation under Section 8.3(a) is not finally resolved
within thirty (30) days following receipt by either Licensor or the BMS Partner of a Dispute Resolution Notice, the Dispute shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the
“ICC”). The arbitral tribunal shall be composed of three (3) arbitrators. Each of Licensor and the BMS Partner shall nominate one (1) arbitrator. The two (2) arbitrators so nominated shall nominate the presiding
arbitrator. If either Licensor or the BMS Partner fails to nominate an arbitrator in its Request for Arbitration or within thirty (30) days of receiving written notice of the nomination of an arbitrator by the other party, such arbitrator shall
be appointed by the ICC Court. If the two (2) arbitrators to be nominated by Licensor and the BMS Partner fail to agree upon a third arbitrator within thirty (30) days of the nomination of the second arbitrator, the third arbitrator shall
be appointed by the ICC Court. The place of arbitration shall be Paris, France and the language of the arbitration shall be English. Notwithstanding any provision to the contrary in the ICC Rules of Arbitration, each party shall bear its own costs
and expenses relating to such arbitration and all related proceedings, including fees for legal representation. Each Party shall continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect while the
Dispute is being resolved. The Parties agree that any dispute arising out of or relating to this Agreement, the Definitive Agreement, or the Settlement Agreement (including the China Opt-Out Letter) or any Alliance Agreement (as such terms are
defined in the Definitive Agreement) shall be resolved in a single arbitration before the ICC, regardless of how many parties or agreements are implicated, and specifically waive any argument that a dispute arising out of or relating to this
Agreement shall be resolved in multiple arbitrations before the ICC. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 15 

 8.4. Specific Performance. Each Party agrees that the Licensed Intellectual Property
is unique, and each Party hereby acknowledges and agrees that it and the other Party would be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached.
Accordingly, each Party shall be entitled to seek specific performance and/or interim relief, and agrees that the arbitral tribunal constituted under Section 8.3(b) shall have the power to order specific performance or grant provisional,
interim, or conservatory measures, including but not limited to provisional injunctive relief. The Parties undertake to comply forthwith with any such provisional, interim, or conservatory measures ordered by the arbitral tribunal and agree that
such measures may, to the extent not precluded by applicable law, be enforceable as a final award in any court of competent jurisdiction. For the avoidance of doubt, nothing in this provision shall prevent any Party from seeking conservatory or
interim measures, including, but not limited to, temporary restraining orders or preliminary injunctions or their equivalent, from any court of competent jurisdiction before the arbitral tribunal is constituted under Section 8.3(b) or,
thereafter, upon the order of the arbitral tribunal. 
 8.5. No Third Party Beneficiaries. This Agreement shall be
binding upon and inure solely to the benefit of the Parties (including the Sanofi Partner and the BMS Partner, each in its capacity as a partner of the SNC Partnership) and permitted sub-licensees and assigns, and nothing herein, express or implied,
is intended to, or shall confer upon, any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 
 8.6. Assignment. 
 (a) Neither of the Parties hereto may assign any of its
rights or obligations to a Third Party under this Agreement without the prior written consent of the other Parties and BMS and any assignment without such consent shall be null and void and of no effect. Each Party may assign any of its rights or
obligations under this Agreement to an Affiliate of such Party without the prior written consent of the other Parties and BMS, provided that the assigning Party shall remain liable for its Affiliate’s performance hereunder. 

(b) In no event shall the SNC Partnership or its Affiliates be restricted in their ability to appoint distributors for Clopidogrel
Products or to sublicense their rights hereunder in accordance with the terms hereof, so long as such appointment or sublicensing does not or would not reasonably be expected to result in an assignment in violation of this Section 8.6.
Notwithstanding the foregoing, Sanofi and its Affiliates shall be permitted to assign this Agreement without BMS’s consent in connection with any divestiture permitted under Section 12.7 of the Definitive Agreement. 

8.7. Severability. If any term or other provision hereof is held to be invalid, illegal or incapable of being enforced by
applicable law or public policy, all other terms and provisions hereof shall nevertheless remain in full force and effect so long as the economic effect or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of
the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 16 

 8.8. Waivers and Amendments. No modification of or amendment to this Agreement shall
be valid unless (i) in a writing signed by both Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same and (ii) BMS has provided its prior written consent to such modification
or amendment. Any waiver of any term or condition of this Agreement shall be in a writing signed by the Party sought to be charged with such waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to
constitute the waiver of any other breach of the same or of any other provision hereof. 
 8.9. Headings. All titles and
captions contained in this Agreement are for the convenience of reference only and shall not affect in any way the meaning or interpretation hereof. 
 8.10. Entire Agreement. This Agreement constitutes the entire agreement of the Parties with respect to the subject matter contained herein and all prior agreements relative thereto which are not
contained herein are hereby terminated. 
 8.11. No Partnership or Joint Venture. This Agreement is not intended to
create, and nothing contained herein shall be construed to create an association, joint venture, trust or partnership, or to impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be
severally responsible for its own covenants, obligations and liabilities as herein provided. Other than the SNC Partnership: (i) no Party shall be under the control of, or shall be deemed to control any other Party; (ii) no Party is the
legal representative, agent, joint venturer or employee of the other Party with respect to this Agreement for any purpose whatsoever, and no Party shall have the right or power to bind the other Party; and (iii) no Party has the right or
authority to assume or create any obligations of any kind or to make any representation or warranty on behalf of any other Party, whether express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are
intended only for the regulation of relations between the Parties. This Agreement is not intended for the benefit of non-Party creditors, and no rights are granted to non-Party creditors under this Agreement. 

8.12. BMS Partner. At such time as the BMS Partner shall cease to hold any direct or indirect ownership interest in the SNC
Partnership, all rights and obligations of BMS and the BMS Partner contained herein shall terminate, except (i) rights and obligations accrued prior to the date that the BMS Partner ceased to hold any ownership interest in the SNC Partnership,
and (ii) as set forth in Section 2.1 with respect to BMS’s rights under the New IP Agreement. 
 8.13.
Governing Language. The Parties acknowledge that this Agreement may be translated into the French language. The Parties agree that this English language version shall in all respects be the controlling version of this Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 17 

 8.14. Force Majeure. No Party shall be in default under this Agreement, or shall have
any obligation to the other Party, if such Party is unable to perform under this Agreement by reason of act of God, fire, flood, strike, national emergency or other contingency beyond its reasonable control (a “Force Majeure”). Such
Party shall give the other Party prompt notice of any interruption of performance on account of Force Majeure, and of the resumption of such performance, and shall keep the other Party informed on a current basis as to the steps being taken to
remove, and the anticipated time of removal of, the circumstances resulting in such Force Majeure. Notwithstanding the foregoing, nothing in this Section 8.14 shall excuse or suspend the obligation to make any payment due under this Agreement
in the manner and at the time provided herein. 
 8.15. Counterparts. This Agreement may be executed in one or more
counterparts, each of which when executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same agreement. 
 8.16. Definitive Agreement. For so long as (i) the SNC Partnership is a party to this Agreement and (ii) BMS retains any direct or indirect ownership interest in the SNC Partnership, in
the event of any conflict or inconsistency between any provision of this Agreement and the terms of the Definitive Agreement, the Definitive Agreement shall govern with respect to such provision. 

[Remainder of Page Intentionally Left Blank] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 18 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year
first written above. 
  

									
	SANOFI	 		 	SANOFI PHARMA BRISTOL-MYERS SQUIBB
				
	By:	 	/s/ Thierry Saugier	 		 	Represented by:
		 	Name: Thierry Saugier	 		 		 	
		 	Title:   Authorized representative	 		 	SANOFI PARTICIPATIONS
					
		 		 		 	By:	 	/s/ Thierry Saugier
		 		 		 		 	Name: Thierry Saugier
		 		 		 		 	Title:   Authorized representative
				
		 		 		 	Witnessed by:
				
		 		 		 	BMS INVESTCO S.A.S.
					
		 		 		 	By:	 	/s/ Jean-Christophe Barland
		 		 		 		 	Name: Jean-Christophe Barland
		 		 		 		 	Title:   CEO

 [Signature Page to Amended and Restated Territory A Clopidogrel License] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1A 

LICENSED PATENTS 

[*][NOTE: APPROXIMATELY FIVE PAGES OF TEXT ARE OMITTED] 
  

													
	 Country
	 	 Filing
	 	 Application
	  	Grant	  	Patent	  	Expiry	  	Status

 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 Schedule 1A -
2 

 SCHEDULE 1B 

LICENSED TRADEMARKS 
  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 [*][NOTE: APPROXIMATELY 11 PAGES OF TEXT ARE OMITTED] 

 

																	
	 Trademark
	  	Country	  	Class	  	Filing date	  	Filing number	  	Registration date	  	Registration number	  	Current status	  	Next renewal

 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 Schedule 1B -
1 

 SCHEDULE 1C 

TERRITORY
A1 

-     Austria 

-     France (metropolitan) 

-     Belgium 
 -
    Cyprus 
 -     Denmark 
 -     Finland 
 -     Germany 

-     Greece 

-     Hong-Kong 

-     Iceland 

-     Ireland 

-     Israel 

-     Italy 

-     Korea 

-     Norway 

-     United Kingdom 

-     the Netherlands 

-     Portugal 

-     Spain 

-     Sweden 

-     Switzerland 

-     Taiwan 

 

	1 	Territory A will be deemed to include any new country created by the division, consolidation or name change of the countries listed below. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.w

 Exhibit 10w 
 *Confidential Treatment Requested 
  

 
  

AMENDED AND RESTATED 
 CLOPIDOGREL 
 INTELLECTUAL PROPERTY LICENSE 

AGREEMENT 
 between

 SANOFI 

and 
 BRISTOL-MYERS
SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP 
 dated as of January 1, 2013 

 
  

 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
	ARTICLE 1	  
	DEFINITIONS	  
			
	 1.1
	  	Defined Terms	  	 	2	  
	 1.2
	  	Additional Defined Terms	  	 	5	  
	
	ARTICLE 2	  
	GRANT OF LICENSE	  
			
	 2.1
	  	License Grant	  	 	6	  
	 2.2
	  	No Transfer	  	 	6	  
	 2.3
	  	No Implicit Rights	  	 	7	  
	 2.4
	  	Goodwill	  	 	7	  
	 2.5
	  	Improvements	  	 	7	  
	 2.6
	  	Original License	  	 	7	  
	
	ARTICLE 3	  
	SUB-LICENSE	  
			
	 3.1
	  	General Sub-License	  	 	7	  
	 3.2
	  	Sub-License for Alliance Agreements	  	 	7	  
	 3.3
	  	Termination of Sub-License	  	 	7	  
	
	ARTICLE 4	 
	CONSIDERATION	 
			
	 4.1
	  	Discoverer’s Remuneration	  	 	8	  
	 4.2
	  	Payment	  	 	8	  
	 4.3
	  	Method of Payment	  	 	8	  
	 4.4
	  	Records	  	 	8	  
	 4.5
	  	Payment Reports	  	 	8	  
	 4.6
	  	Taxes	  	 	9	  
	
	ARTICLE 5	  
	TRADEMARKS; PATENTS; INFRINGEMENT	  
			
	 5.1
	  	Maintenance	  	 	9	  
	 5.2
	  	Registration	  	 	9	  
	 5.3
	  	Undertaking of the Partnership	  	 	9	  
	 5.4
	  	Compliance	  	 	9	  
	 5.5
	  	Quality Standards	  	 	10	  
	 5.6
	  	Quality Control	  	 	10	  
	 5.7
	  	Failure to Meet Standards	  	 	10	  
	 5.8
	  	Patent and Trademark Infringement	  	 	10	  
	 5.9
	  	Notification of Infringement	  	 	11	  
	 5.10
	  	Invalidity or Nullity	  	 	11	  
	 5.11
	  	[*]	  	 	12	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 i 

							
	
	ARTICLE 6	  
	TERM; TERMINATION	  
			
	 6.1
	  	Term; Termination	  	 	12	  
	 6.2
	  	Consequences of Termination	  	 	13	  
	
	ARTICLE 7	  
	CONFIDENTIALITY	  
	
	ARTICLE 8	  
	MISCELLANEOUS	  
			
	 8.1
	  	Notices	  	 	14	  
	 8.2
	  	Governing Law	  	 	15	  
	 8.3
	  	Dispute Resolution	  	 	15	  
	 8.4
	  	Specific Performance	  	 	16	  
	 8.5
	  	No Third Party Beneficiaries	  	 	16	  
	 8.6
	  	Assignment	  	 	17	  
	 8.7
	  	Severability	  	 	17	  
	 8.8
	  	Waivers and Amendments	  	 	17	  
	 8.9
	  	Headings	  	 	17	  
	 8.10
	  	Entire Agreement	  	 	17	  
	 8.11
	  	No Partnership or Joint Venture	  	 	18	  
	 8.12
	  	Governing Language	  	 	18	  
	 8.13
	  	Force Majeure	  	 	18	  
	 8.14
	  	Counterparts	  	 	18	  

 SCHEDULES 
  

			
	SCHEDULE 1A	  	LICENSED PATENTS
	SCHEDULE 1B	  	LICENSED TRADEMARKS

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 ii 

 This AMENDED AND RESTATED CLOPIDOGREL INTELLECTUAL PROPERTY LICENSE (this
“Agreement”) dated as of January 1, 2013 is hereby made by and between: 
 Sanofi, a
société anonyme organized and existing under the laws of the French Republic (“Licensor”); and 
 Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, a Delaware partnership (the “Partnership”) and, together with Licensor, the “Parties” and, individually,
each a “Party”). 
 W I T N E S S E T H: 

WHEREAS, Licensor previously discovered and patented a new chemical entity known as SR 25990C with the international non-proprietary name
Clopidogrel Hydrogenosulphate (“Clopidogrel”); 
 WHEREAS, Licensor, Bristol-Myers Squibb Company, a Delaware
corporation (“BMS”) and Sterling Winthrop, Inc., a Delaware corporation (“Sterling”) entered into a Development Agreement dated July 29, 1993 (the “Development Agreement”) for, among other
things, the development of Clopidogrel; 
 WHEREAS, pursuant to an Amended and Restated Asset Purchase Agreement dated as of
September 30, 1994 among Eastman Kodak Company, Licensor and Sterling, Licensor acquired certain assets, and assumed certain obligations, of the ethical pharmaceutical business of Sterling, including the rights and obligations of Sterling under
the Development Agreement; 
 WHEREAS, Licensor and BMS have entered into a Territory B Alliance Support Agreement dated as of
January 1, 1997, as amended as of the date hereof (the “Alliance Support Agreement”) and have formed through their indirect wholly owned subsidiaries the Partnership pursuant to the partnership agreement dated as of
January 1, 1997, as amended as of the date hereof (the “Partnership Agreement”) for, among other things, the commercialization of Clopidogrel Products in certain territories, including Territory B (as such terms are defined
herein); 
 WHEREAS, Licensor, BMS and the Partnership have entered into a Product Know-How License Agreement for Territory B
dated as of January 1, 1997, as amended as of the date hereof (the “Know-How License Agreement”), pursuant to which Licensor and BMS have granted to the Partnership a license to use certain know-how for the commercialization of
Clopidogrel Products and which was developed by Licensor and BMS under the Development Agreement; 
 WHEREAS, Licensor owns or
has acquired independent of BMS certain intellectual property, including certain patents, trademarks and know-how, for the commercialization of Clopidogrel Products in certain territories, including Territory B; 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 WHEREAS, Licensor and the Partnership have entered into a Clopidogrel Intellectual Property
License and Supply Agreement, dated as of January 1, 1997, as amended by the Amendment to the Clopidogrel Intellectual Property License and Supply Agreement, dated December 6, 2007 (as amended, the “Original License”),
pursuant to which Licensor granted to the Partnership a license under certain intellectual property, including certain patents, trademarks and know-how, for the commercialization of Clopidogrel Products in certain territories, including Territory B;

 WHEREAS, the Partnership has been commercializing Clopidogrel Products in Territory B since that date; 

WHEREAS, Licensor and its Affiliates have the exclusive right, subject to the terms and conditions set forth in this Agreement, to
provide the active substance chemical bulk containing Clopidogrel (the “Clopidogrel Bulk”) that is required for the development, clinical testing and manufacturing of Clopidogrel Products in Territory B; 

WHEREAS, pursuant to the Master Restructuring Agreement (the “Definitive Agreement”), dated as of September 27,
2012, by and between Licensor and BMS, Licensor and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to Clopidogrel Products, other than in the United States and Puerto Rico; and

 WHEREAS, in connection with the transactions contemplated by the Definitive Agreement, Licensor and BMS have agreed to, among
other things, amend and restate the Original License on the terms set forth herein. 
 NOW, THEREFORE, in consideration of the
mutual covenants and the terms and conditions set forth herein, the Parties hereby agree as follows: 
 ARTICLE 1

 DEFINITIONS 
 1.1 Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 
 “Affiliate,” when used with reference to any Person, means any other Person controlling, controlled by, or under common control with, such Person; provided, however, that, with respect to
Sanofi, the definition of Affiliate shall exclude L’Oréal, a société anonyme organized and existing under the laws of the French Republic. For the purposes of this definition, “control” shall refer to
(a) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto any material decision relating to the management or policies of a Person, in each case whether through the ownership of voting
securities, by contract or otherwise; (b) the beneficial ownership, directly or indirectly, of securities (excluding general partnership interests) representing at least 50% of the voting power of all outstanding voting securities of a Person;
or (c) the beneficial ownership of at least 50% of the partnership interests of a general partnership. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2 

 “Alliance Agreements” has the meaning set forth in the
Alliance Support Agreement. 
 “Alliance Strategic Committee” has the meaning set forth in the
Alliance Support Agreement. 
 “BMS Partner” means Bristol-Myers Squibb Investco, L.L.C., a
partner in the Partnership. 
 “Clopidogrel Intellectual Property” means the Clopidogrel
Know-How and the Licensed Patents. 
 “Clopidogrel Know-How” means any and all technical data,
information, material and other know-how that relate to the manufacturing and purification of the Clopidogrel Bulk, including, without limitation, any analytical methodology, chemical, procedures, protocols, techniques and results of experimentation
and testing, solely owned, developed or acquired by Licensor and its Affiliates as of the date hereof. 

“Clopidogrel Product” means the product or products having as an active ingredient Clopidogrel or any
salt, ester, metabolite or pro-drug thereof. 
 “fixed dose combination” means a pharmaceutical
dosage form containing fixed doses of more than one active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in which separate drugs in
separate dosage forms are sold in a single unit or bundle. 
 “Fixed Dose Combination Product”
means a fixed dose combination containing Clopidogrel. 
 “Functional Committee” means any
Alliance Functional Committee (as such term is defined in the Alliance Support Agreement) or any License Functional Committee (as such term is defined in the Know-How License Agreement). 

“Governmental Authority” means any federal, state or local or any foreign or supranational government,
governmental, regulatory or administrative authority, agency or commission or any court, tribunal or judicial or arbitral body. 
 “License Steering Committee” has the meaning set forth in the Know-How License Agreement. 
 “Licensed Intellectual Property” means the Clopidogrel Intellectual Property and the Product Intellectual Property. 

“Licensed Patents” means the patents and patent applications of Licensor and its Affiliates existing on
the date hereof that relate to Clopidogrel and Clopidogrel Products, as listed on Schedule 1A attached hereto and all reissues, renewals, divisions, continuations, continuations-in-part, reexaminations, patent term restorations, patents of
additions and extensions thereof. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3 

 “Licensed Trademarks” means the trademarks and registered
trademarks and applications for registered trademarks in Territory B listed on Schedule 1B attached hereto, and any trademarks, registered trademarks and applications for registered trademarks that are confusingly similar to or replacements
for the foregoing and that are selected by Licensor for use in connection with Clopidogrel Product. 

“Line Extension” has the meaning set forth in the Know-How License Agreement. 

“MAA” means any marketing authorizations, licenses, approvals, registrations, certificates and exemptions
submitted to or granted by or pending with any Governmental Authority for the purpose of allowing the manufacture, production, supply, marketing, distribution or sale of any Clopidogrel Product in a particular country. 

“Marketing Entity” has the meaning set forth in the Partnership Agreement. 

“Net Sales” means for any given period and with respect to any Clopidogrel Product, the gross amount
invoiced in respect thereof by the Marketing Entities to any Person (excluding any transfers between any Party and its Affiliates solely for purposes of resale, promotional use or clinical trials), less (i) quantity and/or cash
discounts, allowances and/or rebates actually allowed or given, (ii) freight, postage and shipping insurance expenses (if separately identified in such invoice), (iii) sales taxes directly related to the sale to the extent included in the
gross invoice price (but not including taxes assessed against the income derived from such sale) and (iv) amounts repaid or credited on account of rejections, outdating or the return of such Clopidogrel Product, provided that the [*].

 “New Drug Application” means the application required to be filed with the relevant
Governmental Authority in any country in order to obtain approval to market commercially any Clopidogrel Product in such country. 
 “New Indication” has the meaning set forth in the Know-How License Agreement. 
 “New IP Agreement” means the FDC Intellectual Property License Agreement between Licensor and BMS, dated as of the date hereof. 

“Person” means any individual, partnership, firm, corporation, société anonyme,
société en nom collectif, société en participation, société par actions simplifiée, limited liability company, joint venture, association, trust or other entity or any government
or any agency or political subdivision thereof, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4 

 “Product Intellectual Property” means the Product Know-How,
the Licensed Trademarks and the Licensed Patents. 
 “Product Know-How” means any and all
technical data, information, material and other know-how that relate to the formulation of Clopidogrel Products, including, without limitation, any analytical methodology, chemical, toxicological, pharmacological and clinical data, formulae,
procedures, protocols, techniques and results of experimentation and testing, solely owned, developed or acquired by Licensor as of the date hereof. 
 “Safety Problem” has the meaning set forth in the Alliance Support Agreement. 
 “Sanofi Partner” means sanofi-aventis U.S. LLC, a partner in the Partnership. 
 “Territory B” or the “United States” means any State or Commonwealth of the United States of America, the District of Columbia, Puerto Rico, the U.S. Virgin Islands,
Guam, American Samoa and any other territory, possession or military base of the United States of America. 

“Third Party” means a Person who or which is neither a Party nor an Affiliate of a Party. 

“U.S. Excise Tax” shall mean the “Annual Fee on Branded Prescription Pharmaceutical
Manufacturers” payable by the U.S. Plavix Partnership to the U.S. government under Section 9008 of the Patient Protection and Affordable Health Care Act of 2010, as amended by Section 1404 of the Health Care and Education
Reconciliation Act of 2010, enacted into law by the United States Congress on 23 March 2010 and amended on 30 March 2010. H.R. 3590, Pub. L. No. 111-148, 124 Stat. 119 (2010), as amended by H.R. 4872, Pub. L. No. 111-152, 124
Stat. 1029 (2010), as the same may hereafter be modified by any successor legislation thereto. 
 “U.S.
Plavix Partnership” shall mean Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, the partnership established pursuant to the Partnership Agreement effective as of October 1, 1997 between E.R. Squibb & Sons, Inc. and
sanofi-aventis U.S. LLC, as amended. 
 1.2 Additional Defined Terms. The following additional defined terms shall have
the meanings set forth in the sections of this Agreement listed below: 
  

			
	 Defined Term
	  	 Section Where Defined

	Agreement	  	Preamble
	Alliance Support Agreement	  	Recitals
	BMS	  	Recitals
	Clopidogrel	  	Recitals
	Clopidogrel Bulk	  	Recitals
	Definitive Agreement	  	Recitals

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5 

			
	 Defined Term
	  	 Section Where Defined

	Development Agreement	  	Recitals
	Dispute	  	8.3
	Dispute Resolution Notice	  	8.3
	 Force Majeure

ICC
	  	 8.13
 8.3

	Know-How License Agreement	  	Recitals
	License Termination Date	  	6.2(a)
	Licensor	  	Preamble
	Notices	  	8.1
	Original License	  	Recitals
	Partnership Agreement	  	Recitals
	Partnership	  	Preamble
	Party	  	Preamble
	Payment Report	  	4.3
	 Plavix Supply Agreement

Quality Standards
	  	 2.1
 5.5

	Sterling	  	Recitals

 ARTICLE 2 
 GRANT OF LICENSE 
 2.1 License Grant. Subject to the terms and
conditions of this Agreement, Licensor hereby grants to the Partnership, and the Partnership hereby accepts, an exclusive license for the term hereof under the Product Intellectual Property (a) to sell, offer for sale and import Clopidogrel
Products in Territory B, and (b) to develop Clopidogrel Products for Territory B, including, without limitation, New Indications and Line Extensions thereof; provided that the foregoing exclusivity granted in paragraphs (a) and
(b) shall not apply to Licensor and BMS to the extent of their respective rights (both granted and retained) under the New IP Agreement with respect to Fixed Dose Combination Products. 

Subject to the occurrence of a change in exclusivity of supply under Section 4.3 of the Plavix Finished Product Supply Agreement
(“Plavix Supply Agreement”) between sanofi-aventis U.S. LLC, as supplier, and the Partnership, as purchaser, dated as of the date hereof, Licensor hereby grants to the Partnership, subject to the terms and conditions of this
Agreement, an exclusive license under the Product Intellectual Property to manufacture and package, or have manufactured and packaged, the Clopidogrel Products for sale in Territory B, for the term and to the extent needed to cover the period of
exclusivity change. 
 2.2 No Transfer. The Partnership hereby acknowledges and agrees that this Agreement does not, and
shall not be deemed to, transfer any proprietary ownership interest whatsoever to the Partnership in or to the Licensed Intellectual Property. Nothing herein shall give the Partnership any right, title or interest in or to any of the Licensed
Intellectual Property, except the rights granted pursuant to this Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6 

 2.3 No Implicit Rights. All of the rights granted hereunder are explicitly stated
herein and nothing in this Agreement shall be construed to grant any implied rights whatsoever to the Partnership in or to the Licensed Intellectual Property. 
 2.4 Goodwill. The Partnership hereby acknowledges that all goodwill connected with the Licensed Trademarks shall inure to the benefit of Licensor, and the Partnership shall not take any action that
may be detrimental to such goodwill. 
 2.5 Improvements. Any new or useful invention, process or improvement, patentable
or unpatentable, relating to the formulation of any Clopidogrel Product under the Clopidogrel Intellectual Property developed or acquired by the Partnership during the term hereof shall be the property of the Partnership, which shall have all
ownership rights thereto. 
 2.6 Original License. The Parties hereby agree that all acts, omissions and occurrences
prior to the date hereof, and all rights and obligations of the Parties with respect thereto, shall be governed by the terms of the Original License prior to its amendment and restatement in accordance with the terms hereof. 

ARTICLE 3 

SUB-LICENSE 
 3.1 General Sub-License. Except as permitted under Section 3.2 hereof, the Partnership shall not, without the prior written consent of Licensor, sub-license any of its rights and obligations
under this Agreement; provided, however, that if the representatives of Licensor on any Functional Committee, the Alliance Strategic Committee or the License Steering Committee consensually agree to sub-license any of the Partnership’s
rights or obligations hereunder, such agreement shall be deemed to be Licensor’s consent for the purposes of this Section 3.1. No such sub-license shall relieve the Partnership of its obligations hereunder. 

3.2 Sub-License for Alliance Agreements. The Partnership shall sub-license those of its rights and obligations under this
Agreement, to any Affiliate of Licensor or BMS that is a party to any Alliance Agreement, solely for the purposes of permitting such Affiliate to perform its obligations under such Alliance Agreement. 

3.3 Termination of Sub-License. Licensor shall have the right to require the Partnership to terminate any sub-license hereunder in
the event that the sub-licensee fails to comply in any material respect with, or takes any action contrary to, the terms of such sub-license or any decision made by any Functional Committee, the Alliance Strategic Committee or the License Steering
Committee, and such sub-licensee has failed to remedy such non-compliance within thirty (30) days from its receipt of written notice thereof from Licensor or the Partnership. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7 

 ARTICLE 4 
 CONSIDERATION 
 4.1 Discoverer’s Remuneration. In consideration
of the rights and licenses granted hereunder, the Partnership shall pay, or shall cause to be paid, directly to Licensor for the term hereof a [*] in the amount of [*] of Net Sales of Clopidogrel Products in Territory B. 

4.2 Payment. For the term of this Agreement, the Partnership shall pay or cause to be paid to Licensor all amounts due hereunder
on a quarterly basis within sixty (60) days of the end of each calendar quarter. Each such payment shall be accompanied by an accurate statement of the amount of Net Sales of Clopidogrel Products in Territory B during such calendar quarter and
the calculation of all payments to be made to Licensor for such calendar quarter (each a “Payment Report”). 

4.3 Method of Payment. All payments to be made hereunder shall be made by wire transfer in immediately available funds, and shall
be made in US dollars to the bank account of Licensor as notified to the Partnership, unless the Parties agree to settle such payments through other means. 
 4.4 Records. The Partnership shall maintain (i) books, records and accounts which accurately and fairly reflect, in reasonable detail, the Net Sales of Clopidogrel Products in Territory B and
(ii) an adequate system of internal accounting controls. All books, records and accounts referred to in clause (i) above shall be maintained for not less than [*], or for such longer period if and as required by applicable law, following
the date of the sales constituting the Net Sales and shall be made available for reasonable review upon request by Licensor. 

4.5 Payment Reports. (a) At the request of Licensor, the Partnership shall, and shall if applicable cause its sub-licensees
to, permit Licensor or an independent, certified public accountant not having any significant relation to either BMS or Licensor, as appointed by Licensor, at reasonable times and upon reasonable notice, to examine the books and records of the
Partnership as may be necessary to (i) determine, with respect to any calendar quarter ending not more than [*] prior to the related request, the correctness of any Payment Report or payment made under this Agreement or any Alliance Agreement
or (ii) obtain information as to the amount payable for any such calendar quarter in the case of failure on the part of the Partnership to report or pay pursuant to this Agreement or on the part of any party to any Alliance Agreement; provided,
however, that Licensor shall not have the right to make such audit request more than once every [*]. The results of any such audit shall be promptly made available to BMS, Licensor and the Partnership. 

(b) Licensor shall bear the full cost and expense of any such audit, unless such audit discloses that the amount due to Licensor is more
than the amount paid by [*] of the amount due, in which case BMS shall bear the full cost and expense of such audit. 
 (c) The
determination by an independent, certified public accountant pursuant to this Section 4.5 as to the amount due and payable by the Partnership shall be conclusive and binding on the Parties hereto. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8 

 4.6 Taxes. All payments due under this Agreement shall be paid in full without
deduction, except for taxes (if any) required to be withheld by applicable law in Territory B with respect to such payments. In the event the Partnership is required under applicable law to withhold any tax to the revenue authorities in any country
in Territory B regarding any payment to Licensor, the amount of such tax shall be deducted by the Partnership and paid to the relevant revenue authority, and the Partnership shall notify Licensor thereof and shall promptly furnish to Licensor all
copies of any tax certificate or other documentation evidencing such withholding. In the event that any such tax shall subsequently be found to be due, payment of such tax shall be the responsibility of Licensor. 

ARTICLE 5 

TRADEMARKS; PATENTS; INFRINGEMENT 
 5.1 Maintenance. Subject to Article X of the Alliance Support Agreement, Licensor shall maintain in full force and effect all Licensed Patents and Licensed Trademarks for the term of this Agreement
and shall bear all costs and expenses related thereto. In the event that Licensor or the Partnership becomes aware of a registration for or an application to register a trademark which it believes is reasonably likely to conflict with any Licensed
Trademark, it shall promptly inform the other Party in writing of the same, giving particulars thereof. Licensor shall have the first right to commence an opposition or cancellation proceeding against such trademark application or registration. If
Licensor decides not to commence an opposition or cancellation proceeding, it shall promptly inform the Partnership in writing of the same and the Partnership shall have the right, but not the obligation to commence an opposition or cancellation
proceeding against the trademark application or registration. The cost and expenses of any such opposition or cancellation proceeding commenced by either Licensor or the Partnership shall be borne by the Partnership. Each Party shall execute all
necessary and proper documents and take such actions as shall be appropriate to assist the other Party in commencing and prosecuting such opposition or cancellation proceeding. 
 5.2 Registration. The Licensed Trademarks in Territory B are filed and shall be maintained in the name of Licensor. The Partnership shall execute and deliver to Licensor, in such form as Licensor
shall reasonably request, any and all documents which may be necessary or desirable to assist Licensor in renewing the Licensed Trademarks, or in recording the Partnership as a registered user of the Licensed Trademarks, if necessary. 

5.3 Undertaking of the Partnership. The Partnership agrees not to register or attempt to register in any country in Territory B any
trade name, trademark, service mark, certification mark or logo that is confusingly similar to, or that contains elements that are confusingly similar to, any Licensed Trademark. 

5.4 Compliance. The Partnership shall comply with all notice and marking requirements under applicable intellectual property laws
and labeling requirements under applicable law that are necessary or advisable for the protection and enforcement of the Licensed Trademarks or the Licensed Patents. The Partnership shall further comply with all applicable laws and regulations
related to the manufacture, marketing, distribution and sale of Clopidogrel Products in Territory B. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9 

 5.5 Quality Standards. Licensor, and where relevant the Partnership pursuant to a
change in exclusivity of supply under the Plavix Supply Agreement, shall make or have made Clopidogrel Products according to the quality standards established in accordance with the New Drug Applications and the MAAs (the “Quality
Standards”). All promotional and packaging materials to be used in connection with Clopidogrel Products shall be submitted to Licensor so that Licensor may ensure the correct use of the Licensed Trademarks thereon, and the Partnership shall
not use any such promotional or packaging materials without the prior consent of Licensor (which consent shall not be unreasonably withheld); provided, however, that such consent shall be deemed to have been given if Licensor shall not have
provided Notice to the Partnership of its objection to any such promotional or packaging material within fifteen (15) days after its receipt thereof, and provided, further, that such consent shall be deemed to have been given with regard
to packaging materials as long as Licensor or Licensor’s Affiliates continue to exclusively pack the Clopidogrel Products under the Plavix Supply Agreement. 
 5.6 Quality Control. If, as a result of a change in exclusivity of supply under the Plavix Supply Agreement, the Partnership uses manufacturers and/or packers other than Licensor or Licensor’s
Affiliates, the Partnership shall carry out quality control tests that are customary in the pharmaceutical industry to determine that all Clopidogrel Products and packaging related thereto sold by or on behalf of the Partnership conform to the
Quality Standards. The Partnership shall keep full and complete testing records, which shall be made available for reasonable review upon request by Licensor. Upon reasonable request, the Partnership shall permit Licensor to inspect the
manufacturing and/or packing facilities used by or on behalf of the Partnership and, during such inspection, Licensor shall have the right to make such tests as it deems necessary to ensure that the Quality Standards are being maintained.

 5.7 Failure to Meet Standards. The Partnership agrees that Clopidogrel Products not meeting the Quality Standards
shall not be labeled or used or offered for sale under the Licensed Trademarks. Unless otherwise agreed, any products that are not Clopidogrel Products may not be advertised or otherwise promoted, directly or indirectly, by the Partnership with any
reference to the Licensed Trademarks, and the Partnership shall instruct its distributors to comply with this restriction. 

5.8 Patent and Trademark Infringement. During the term of this Agreement, if the Partnership or Licensor becomes aware of the
infringement or threatened infringement of any Licensed Patent or Licensed Trademark, it shall promptly notify the other Party in writing of the same, giving particulars thereof. Licensor shall have the first right to institute an action based on
such infringement or threatened infringement and shall be responsible for the conduct of such action. The Partnership shall assist and cooperate with Licensor to the extent necessary in the conduct of such action. If Licensor notifies the
Partnership in writing that it does not propose to take action against the infringer, or if within two (2) months of notification of the infringement or threatened infringement, Licensor has taken no demonstrable action to enjoin or address
such infringement or threatened infringement against the infringer, the Partnership shall 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 10 

 
have the right, but not the obligation, to institute an infringement action. The costs and expenses of any such infringement action (including, without limitation, fees of attorneys and other
professionals) shall be borne by the Partnership. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to institute and prosecute such infringement actions and Licensor
shall, if required, lend its name to enable the Partnership to conduct the proceedings. Any award or other consideration paid by Third Parties as a result of an infringement action (whether by way of settlement or otherwise) shall be allocated
between Licensor and BMS on the basis of [*] applied to the date as of which the award or other consideration is received. 

5.9 Notification of Infringement. In the event of the institution of any suit by a Third Party against either Party or any of
their respective Affiliates for patent and/or trademark infringement and/or infringement of any other intellectual property rights involving Clopidogrel or Clopidogrel Products in Territory B, such Party shall promptly notify the other Party in
writing of such suit. Licensor shall have the first right to conduct the defense of any such suit. Licensor shall notify the Partnership within a reasonable amount of time after notification of the institution of such a suit if it elects not to
defend such suit. If Licensor does not elect to defend such suit, the Partnership shall have the right, but not the obligation, to conduct the defense of such suit. The costs and expenses of any such suit (including, without limitation, fees of
attorneys and other professionals) shall be borne by the Partnership. Each Party hereby agrees to assist and cooperate with the other Party, to the extent necessary, in the defense of such suit. Any award or other consideration paid by a Third Party
as a result of such suit (whether by way of settlement or otherwise) shall be allocated between Licensor and BMS on the basis of [*] applied to the date as of which the award or other consideration is received. 

5.10 Invalidity or Nullity. Licensor shall have the first right to conduct the defense of any suit brought by a Third Party based
on the invalidity or nullity of a Licensed Patent other than an action instituted by way of counterclaim in an action for infringement of a Licensed Patent, in which case the Party conducting the infringement action shall have the right to conduct
the defense. The Partnership shall assist and cooperate with Licensor to the extent necessary in the defense of such suit. If Licensor notifies the Partnership in writing that it does not propose to conduct the defense of such suit, or if within two
(2) months of notification of such suit, Licensor has taken no demonstrable action to conduct the defense of such suit, the Partnership shall have the right, but not the obligation, to conduct the defense of such suit. The costs and expenses of
any such action (including, without limitation, fees of attorneys and other professionals) shall be borne by the Partnership. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the
other Party to conduct the defense of such suit and Licensor shall, if required, lend its name to enable the Partnership to conduct the proceedings. Any award or other consideration paid by a Third Party as a result of such suit (whether by way of
settlement or otherwise) shall be allocated between Licensor and BMS on the basis of [*] applied to the date as of which the award or other consideration is received. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 11 

 5.11 [*] Notwithstanding anything to the contrary contained herein or in the Alliance
Support Agreement, Licensor shall have no obligation to maintain, prosecute or defend any patent set forth on Schedule 1A hereto under the heading [*]. 
 ARTICLE 6 
 TERM; TERMINATION 

6.1 Term; Termination. (a) The term of this Agreement shall commence on the date hereof and shall expire on December [*],
2019. Thereafter, the term of this Agreement may be renewed for successive three-year terms by the mutual agreement of the Parties no later than 24 months prior to the expiration of the term then in effect. 

(b) Notwithstanding the foregoing, this Agreement shall automatically expire upon the earlier of (i) the termination by both Parties
of the commercialization of Clopidogrel Products throughout Territory B as the result of a Safety Problem pursuant to Section 7.04 (iii) of the Alliance Support Agreement and (ii) the exercise by BMS of the special put option pursuant
to Section 7.08 of the Alliance Support Agreement. 
 (c) This Agreement may be terminated by the mutual written consent of
each of Licensor, the Sanofi Partner and the BMS Partner. 
 (d) Licensor shall have the right to declare termination of this
Agreement upon Notice to the Partnership, following the first to occur of: 
 (i) the BMS Partner shall have
(A) voluntarily commenced any proceeding or filed any petition seeking relief under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy, insolvency or
similar law of the United States, any state thereof, the French Republic or any other applicable jurisdiction, (B) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or
similar official for it or for all or substantially all of its property, (C) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (D) made a general assignment for the
benefit of creditors of all or substantially all of its assets, (E) become unable generally, or admitted in writing its inability to, pay all or substantially all of its debts as they become due or (F) taken corporate action for the
purpose of effecting any of the foregoing; or 
 (ii) an involuntary proceeding shall have been commenced or any
involuntary petition shall have been filed in a court of competent jurisdiction seeking (A) relief in respect of the BMS Partner, or of its property, under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative
part as well as regulatory part) or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the French Republic or any other applicable jurisdiction, (B) the appointment of a receiver, trustee, custodian,
sequestrator, conciliator, administrator or similar official for the BMS Partner or for all or substantially all of its property or (C) the winding-up or liquidation of the BMS Partner; and such proceeding or petition shall have continued
undismissed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall have continued unstayed and in effect for thirty (30) days. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 12 

 6.2 Consequences of Termination. (a) Upon the expiration or early termination of
this Agreement pursuant to Section 6.1 hereof (the “License Termination Date”): 
 (i) the
terms and conditions of Section 7.07 of the Alliance Support Agreement shall apply, except in the event of early termination pursuant to Section 6.1(b) hereof; 

(ii) the Partnership shall cease, and shall cause each sub-licensee (if any) to cease, all activities related to the
Licensed Intellectual Property; and 
 (iii) the Partnership shall pay in full all amounts due to Licensor
hereunder within ten (10) days after the final determination of Net Sales for such period, including the License Termination Date, pursuant to Sections 4.2, 4.3 and 4.5 hereof which shall survive until the full payment of all amounts under this
clause (iii). 
 (b) In the event of the termination of the commercialization of the Clopidogrel Products in any country of
Territory B pursuant to Section 7.02 of the Alliance Support Agreement: 
 (i) the terms and conditions of
Section 6.2(a)(ii)-(iii) hereof shall apply, mutatis mutandis, with respect to such country; and 
 (ii) all rights and licenses granted by Licensor hereunder with respect to such country shall revert to Licensor, subject to Section 7.03 of the Alliance Support Agreement. 

(c) Expiration or early termination of this Agreement pursuant to this Article 6 shall be without prejudice to any rights which shall have
accrued to the benefit of any Party prior to such expiration or termination. Such expiration or termination shall not relieve any Party from its obligations which are expressly indicated to survive the expiration or termination of this Agreement.
All of the Parties’ rights and obligations under this subclause (c) and under Sections 4.4, 4.5, 4.6, 6.2, 8.2-8.4, Article 7 and, with respect to actions or suits commenced prior to the date of expiration or early termination hereof and
until each such action or suit is finally resolved, Sections 5.1, 5.8, 5.9 and 5.10 hereof, shall survive such expiration or termination for the applicable period. 
 ARTICLE 7 
 CONFIDENTIALITY 

All of the data, material and information exchanged by the Parties hereunder or related hereto (including, without limitation, the
Licensed Intellectual Property) shall be subject to the confidentiality provisions of the Alliance Support Agreement as set forth in Section 5.03 thereof. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 13 

 ARTICLE 8 
 MISCELLANEOUS 
 8.1 Notices. All notices, requests or other
communications hereunder (collectively, “Notices”) shall be in writing, shall be in the English language and shall be given or made by delivery in person, by courier service, by facsimile (with receipt confirmed) or by registered or
certified mail (return receipt requested, with postage prepaid) to the respective Parties at the following addresses: 
 If to
Licensor, to: 
 Sanofi 
 54, rue la Boétie 
 75008 Paris, France 

Attention: Senior Vice President, Legal Affairs and General Counsel 

Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 
 Facsimile: (33.1)
53.77.40.99 
 with a copy to: 
 Weil Gotshal & Manges 
 767 Fifth Avenue 

New York NY 10153 
 Attention: [omitted] 
 Facsimile: 212 310 8007 

If to the Partnership, to: 
 Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership 
 P.O. Box 4000

 Route 206 & Province Line Road 
 Princeton, NJ 08543-4000, USA 
 Attention: Vice President and Associate General
Counsel, Transactional Practice Group 
 Facsimile: (1 609) 252-7680 

with a copy to each of: 
 sanofi-aventis U.S. LLC 
 55 Corporate Drive 

Bridgewater, NJ 08807 USA 
 Attention: [omitted] 
 Facsimile: (908) 981-5705 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 14 

 [omitted]. 
 General Counsel, North America 
 sanofi-aventis U.S. LLC 

55 Corporate Drive 
 Bridgewater, NJ 08807 
 Fax: (908) 981-7833 

and: 
 Sanofi

 54, rue la Boétie 
 75008 Paris, France 
 Attention: Senior Vice President, Legal Affairs and
General Counsel 
 Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 
 Facsimile: (33.1)
53.77.40.99 
 or to such other address or facsimile number as hereafter shall be furnished as provided in this Section 8.1 by any Party
hereto to the other Party hereto. All Notices given to any Party in accordance with this Section 8.1 shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or sent by facsimile, or on the
date ten (10) business days after dispatch by certified or registered mail (postage prepaid) if mailed. 
 8.2 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States of America, without regard to the choice of law principles that might otherwise be applied in such jurisdiction.

 8.3 Dispute Resolution. 
 (a) Negotiation and Notice. In the event of any dispute, claim, controversy or disagreement (each, a “Dispute”) arising out of, in connection with or relating to this Agreement
including any question regarding this Agreement’s existence, validity or termination, the Parties shall first seek resolution of such Dispute by negotiation between their respective senior management. Such negotiation shall be deemed to
commence upon the service by either Licensor or BMS upon the other of a written notice (a “Dispute Resolution Notice”) under this Section 8.3(a). 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 15 

 (b) If a Dispute subject to negotiation under Section 8.3(a) is not finally
resolved within thirty (30) days following receipt by either Licensor or BMS of a Dispute Resolution Notice, the Dispute shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the
“ICC”). The arbitral tribunal shall be composed of three (3) arbitrators. Each of Licensor and BMS shall nominate one (1) arbitrator. The two arbitrators so nominated shall nominate the presiding arbitrator. If either
Licensor or BMS fails to nominate an arbitrator in its Request for Arbitration or within thirty (30) days of receiving written notice of the nomination of an arbitrator by the other Party, such arbitrator shall be appointed by the ICC Court. If
the two (2) arbitrators to be nominated by Licensor and BMS fail to agree upon a third arbitrator within thirty (30) days of the nomination of the second arbitrator, the third arbitrator shall be appointed by the ICC Court. The place of
arbitration shall be Paris, France and the language of the arbitration shall be English. Notwithstanding any provision to the contrary in the ICC Rules of Arbitration, each Party shall bear its own costs and expenses relating to such arbitration and
all related proceedings, including fees for legal representation. Each Party shall continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect while the Dispute is being resolved. The Parties agree
that any dispute arising out of or relating to this Agreement, the Definitive Agreement, or the Settlement Agreement (including the China Opt-Out Letter) or any Alliance Agreement (as such terms are defined in the Definitive Agreement) shall be
resolved in a single arbitration before the ICC, regardless of how many parties or agreements are implicated, and specifically waive any argument that a dispute arising out of or relating to this Agreement shall be resolved in multiple arbitrations
before the ICC. 
 8.4 Specific Performance. Each Party agrees that the Licensed Intellectual Property is unique, and
each Party hereby acknowledges and agrees that it and the other Party would be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached. Accordingly, each
Party shall be entitled to seek specific performance and/or interim relief, and agrees that the arbitral tribunal constituted under Section 8.3(b) shall have the power to order specific performance or grant provisional, interim, or conservatory
measures, including but not limited to provisional injunctive relief. The Parties undertake to comply forthwith with any such provisional, interim, or conservatory measures ordered by the arbitral tribunal and agree that such measures may, to the
extent not precluded by applicable law, be enforceable as a final award in any court of competent jurisdiction. For the avoidance of doubt, nothing in this provision shall prevent any Party from seeking conservatory or interim measures, including,
but not limited to, temporary restraining orders or preliminary injunctions or their equivalent, from any court of competent jurisdiction before the arbitral tribunal is constituted under Section 8.3(b) or, thereafter, upon the order of the
arbitral tribunal. 
 8.5 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the
benefit of the Parties (including the Sanofi Partner and the BMS Partner, each in its capacity as a partner of the Partnership) and permitted sub-licensees and assigns, and nothing herein, express or implied, is intended to, or shall confer upon,
any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 16 

 8.6 Assignment. (a) This Agreement may be assigned by a Party only to an
Affiliate of Licensor or BMS in the event of a corporate reorganization (including an entity that becomes an Affiliate in connection with such reorganization) involving the assumption of all or substantially all of such Party’s marketing or
manufacturing functions in Territory B by such Affiliate, in which event the rights may be assigned and the obligations may be delegated to such Affiliate. 
 (b) Notwithstanding anything to the contrary contained in subclause (a) above, this Agreement may be assigned, in whole or in part, by, or on behalf of, the Partnership as a result of a termination
event under either Section 7.04 or Section 7.06 of the Alliance Support Agreement or as a result of the dissolution of the Partnership (other than for a Safety Problem) and in any such event shall be deemed to be amended and restated
(i) to delete Section 3.2 hereof, as well as any reference to the Alliance Support Agreement, and (ii) to insert those terms and conditions that are then customary in the pharmaceutical industry for an intellectual property license
agreement, including, without limitation, provisions for confidentiality, indemnification and termination for material breach, as well as a diligence requirement that the assignee shall use reasonable commercial efforts to actively promote
Clopidogrel Products (and the remedy for breach of such diligence requirement shall be termination of such amended and restated agreement). 
 8.7 Severability. If any term or other provision hereof is held to be invalid, illegal or incapable of being enforced by applicable law or public policy, all other terms and provisions hereof shall
nevertheless remain in full force and effect so long as the economic effect or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other
provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the
transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 
 8.8 Waivers
and Amendments. No modification of or amendment to this Agreement shall be valid unless in a writing signed by both Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same. Any waiver
of any term or condition of this Agreement shall be in a writing signed by the Party sought to be charged with such waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to constitute the waiver of
any other breach of the same or of any other provision hereof. 
 8.9 Headings. All titles and captions contained in this
Agreement are for the convenience of reference only and shall not affect in any way the meaning or interpretation hereof. 

8.10 Entire Agreement. This Agreement constitutes the entire agreement of the Parties with respect to the subject matter contained
herein and all prior agreements relative thereto which are not contained herein are hereby terminated. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 17 

 8.11 No Partnership or Joint Venture. This Agreement is not intended to create, and
nothing contained herein shall be construed to create an association, joint venture, trust or partnership, or to impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be severally
responsible for its own covenants, obligations and liabilities as herein provided. Other than the Partnership: (i) no Party shall be under the control of, or shall be deemed to control any other Party; (ii) no Party is the legal
representative, agent, joint venturer or employee of the other Party with respect to this Agreement for any purpose whatsoever, and no Party shall have the right or power to bind the other Party; and (iii) no Party has the right or authority to
assume or create any obligations of any kind or to make any representation or warranty on behalf of any other Party, whether express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are intended only
for the regulation of relations between the Parties. This Agreement is not intended for the benefit of non-Party creditors, and no rights are granted to non-Party creditors under this Agreement. 

8.12 Governing Language. The Parties acknowledge that this Agreement may be translated into the French language. The Parties agree
that this English language version shall in all respects be the controlling version of this Agreement. 
 8.13 Force
Majeure. No Party shall be in default under this Agreement, or shall have any obligation to the other Party, if such Party is unable to perform under this Agreement by reason of act of God, fire, flood, strike, national emergency or other
contingency beyond its reasonable control (a “Force Majeure”). Such Party shall give the other Party prompt notice of any interruption of performance on account of Force Majeure, and of the resumption of such performance, and shall
keep the other Party informed on a current basis as to the steps being taken to remove, and the anticipated time of removal of, the circumstances resulting in such Force Majeure. Notwithstanding the foregoing, nothing in this Section 8.13 shall
excuse or suspend the obligation to make any payment due under this Agreement in the manner and at the time provided herein. 

8.14 Counterparts. This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be
an original, but all of which when taken together shall constitute one and the same agreement. 
 [Remainder of Page
Intentionally Left Blank] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 18 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year
first written above. 
  

							
	SANOFI	  	 BRISTOL-MYERS SQUIBB SANOFI
 PHARMACEUTICALS HOLDING
 PARTNERSHIP

				
	By:	 	 /s/ T. Saugier
	  		  	
		 	Name: T. Saugier	  		  	
		 	Title: Authorized representative	  	Represented by:
			
		 		  	 BRISTOL-MYERS SQUIBB

INVESTCO, L.L.C.

				
		 		  	By:	  	 /s/ Katherine Kelly

		 		  		  	Name: Katherine Kelly
		 		  		  	Title: Secretary
			
		 		  	Witnessed by:
			
		 		  	SANOFI-AVENTIS U.S. LLC
				
		 		  	By:	  	 /s/ T. Saugier

		 		  		  	Name: T. Saugier
		 		  		  	Title: Authorized representative

 [Signature Page to Amended and Restated Territory B Clopidogrel License] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1A 

LICENSED PATENTS 

[*][Note: Approximately four pages of text are omitted] 
  

													
	 Country
	  	Filing	  	Application	  	Grant	  	Patent	  	Expiry	  	Status
		  		  		  		  		  		  	
		  		  		  		  		  		  	

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1B 

LICENSED TRADEMARKS 

[*][Table Content Omitted] 
  

																			
	 Trademark
	 	 Country
	 	 Type
	  	Class	  	Current Status	  	Filing No.	  	Filing date	  	Reg. No.	  	Reg. date	  	Next due date

 

																	
	 Trademark
	 	 Country
	 	 Class
	  	Current Status	  	Filing No.	  	Filing date	  	Reg. No.	  	Reg. date	  	Next due date

  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]